In as sub study of a randomized control trial conducted in Sweden, in patients with ST elevated myocardial infarction (STEMI) who are not on ECMO and undergoing primary percutaneous coronary intervention (PCI) and treated with aspirin and potent P2Y12-inhibitors, anticoagulation with bivalirudin was not superior to heparin regarding the composite end point of all-cause death, myocardial infarction, or major bleeding (43). The gene discussed is P2RY12; the disease is ST Elevation Myocardial Infarction.